目的：评价沙利度胺治疗幼年特发性关节炎（juvenile idiopathic arthritis，JIA）的临床疗效和安全性。方法：12例传统治疗方案治疗病情无缓解的JIA患儿，应用沙利度胺治疗（每日2 mg/kg），记录治疗前后患儿的症状、体征、实验室指标及沙利度胺治疗的不良反应。结果：沙利度胺治疗6个月后，患儿泼尼松用量由每日1.92±0.16 mg/kg 降至0.49±0.42 mg/kg (P<0.01)，并有4例能停用泼尼松治疗。12例患儿外周血白细胞计数、ESR、CRP、血清铁蛋白（SF）较治疗前均明显下降（P<0.01）； 8例患儿血红蛋白明显升高(P<0.01)。多关节型JIA患儿平均受累关节数由5个以上降至0～2个（P<0.01），附着点炎症型患儿双“4”字征转阴，Schober′s征转阴。治疗过程中未出现严重不良反应。结论：沙利度胺对JIA有显著的临床疗效，可以作为传统治疗方案无效后的治疗措施。
Abstract
OBJECTIVE: To evaluate the efficacy of thalidomide in the treatment of juvenile idiopathic arthritis (JIA). METHODS: Twelve children with JIA who did not respond to conventional treatment were administered with thalidomide (2 mg/kg daily). The symptoms, signs, and laboratory test results were compared before and after treatment. The thalidomide-related side effects were observed. RESULTS: The average dosage of prednisone was reduced from 1.92±0.16 mg/kg?d to 0.49±0.42 mg/kg?d in the 12 patients 6 months after thalidomide treatment (P<0.01). Four patients did not need prednisone treatment any more. White blood cell count, erythrocyte sedimentation rate (ESR), C reactive protein (CRP) and serum ferritin (SF) significantly decreased after treatment in all of 12 patients (P<0.01). Hemoglobin level increased to normal in 8 patients after treatment (P<0.01). The number of affected joints decreased from 5 before treatment to zero to 2 after treatment in patients with polyarticular JIA (P<0.01). Signs of hip involvement and Schober′s sign turned negative in enthesitis-related cases. No thalidomide-related side effects were observed. CONCLUSIONS: Thalidomide is effective in the treatment of JIA in children who do not respond to conventional treatment.
关键词
幼年特发性关节炎 /
沙利度胺 /
儿童
Key words
Juvenile idiopathic arthritis /
Thalidomide /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］全国儿童风湿病协作组. 儿童风湿病诊断及治疗专家共识（一）［J］. 临床儿科杂志， 2010，28(10):984-991.
［2］Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma［J］. N Engl J Med, 1999, 341(21):1565-1571.
［3］Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma［J］. Cancer, 2005, 104(7):1428-1433.
［4］Cuadrado MJ, Karim Y, Sanna G, Smith E, Khamashta MA, Hughes GR. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens［J］. Am J Med, 2005, 118(3): 246-250.
［5］刘曦，刘爱京，邵福灵.沙利度胺治疗风湿性疾病机制的研究进展［J］.中华风湿病学杂志，2006，10(6):366-368.
［6］周纬. 幼年特发性关节炎治疗进展［J］. 临床儿科杂志，2009，27(2): 117122.
［7］胡坚. 幼年特发性关节炎治疗的观点问题［J］.实用儿科临床杂志，2009，24( 21): 1628-1631.
［8］Breda L, Nozzi M, Sanctis S, Chiarelli F. Laboratory tests in the diagnosis and follow-up of pediatric rheumatic diseases: an update［J］. Semin Arthritis Rheum, 2010, 40（1）: 53-72.
［9］Lazzerini M, Martelossi S, Marchetti F, Scabar A, Bradaschia F, Ronfani L, et al. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results［J］. Aliment Pharmacol Ther, 2007, 25（4）: 419-427.
［10］Galustian C, Labarthe MC, Bartlett JB, Dalgleish AG. Thalidomide-derived immunomodulatory drugs as therapeutic agents［J］. Expert Opin Biot Ther, 2004, 4(12):1963-1970.
［11］Lehman TJ, Striegel KH, Onel KB. Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis［J］. J Pediatr, 2002, 140（1）:125-127.
［12］Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study［J］. J Pediatr, 2004, 145(6): 856-857.
［13］García-Carrasco M, Fuentes-Alexandro S, Escorcega R, Rojas-Rodriguez J, Escobar LE. Efficacy of thalidomide in systemic onset juvenile rheumatoid arthritis［J］. Joint Bone Spine, 2007, 74(5): 500-503.
［14］Quartier P. When should we use TNF antagonists in children with rheumatic disease?［J］. Joint Bone Spine, 2007, 74（1）:1-3.
［15］李亚琴，曹兰芳. 肾上腺糖皮质激素在幼年特发性关节炎中的应用进展［J］. 中国当代儿科杂志，2009，11 (3): 240-242.
PDF(910 KB)
